212 related articles for article (PubMed ID: 27779690)
1. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
[TBL] [Abstract][Full Text] [Related]
2. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
6. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.
Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY
Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212
[TBL] [Abstract][Full Text] [Related]
7. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
8. Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.
Chang JW; Kang SU; Shin YS; Seo SJ; Kim YS; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Sci Rep; 2015 Dec; 5():18208. PubMed ID: 26655729
[TBL] [Abstract][Full Text] [Related]
9. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
10. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
11. Bovine lactoferrin reverses programming of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition in oral squamous cell carcinoma.
Chea C; Miyauchi M; Inubushi T; Okamoto K; Haing S; Nguyen PT; Imanaka H; Takata T
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):142-147. PubMed ID: 30415774
[TBL] [Abstract][Full Text] [Related]
12. A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.
Minabe M; Akiyama Y; Higa K; Tachikawa T; Takahashi S; Nomura T; Kouno M
Exp Dermatol; 2019 May; 28(5):614-617. PubMed ID: 30907457
[TBL] [Abstract][Full Text] [Related]
13. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
16. Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.
Berndt A; Büttner R; Gühne S; Gleinig A; Richter P; Chen Y; Franz M; Liebmann C
Exp Cell Res; 2014 Apr; 322(2):402-14. PubMed ID: 24394543
[TBL] [Abstract][Full Text] [Related]
17. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes.
Harada K; Ferdous T; Ueyama Y
Int J Oncol; 2014 Apr; 44(4):1302-8. PubMed ID: 24452635
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
[TBL] [Abstract][Full Text] [Related]
19. Transcutaneous carbon dioxide suppresses epithelial-mesenchymal transition in oral squamous cell carcinoma.
Iwata E; Hasegawa T; Takeda D; Ueha T; Kawamoto T; Akisue T; Sakai Y; Komori T
Int J Oncol; 2016 Apr; 48(4):1493-8. PubMed ID: 26846904
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor.
Dai W; Li Y; Zhou Q; Xu Z; Sun C; Tan X; Lu L
J Oral Pathol Med; 2014 Apr; 43(4):250-7. PubMed ID: 24020947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
